E-Prescribe QBREXZA with Confidence

Our preferred pharmacy partner, Foundation Care, is at your service.

Foundation Care is a full-service pharmacy that can fill your patient’s QBREXZA prescription and other prescribed medications via mail order.

To quickly and easily e-prescribe QBREXZA:

1( icon)
Select Foundation Care in your e-prescribing system

Foundation Care, LLC
4010 Wedgeway Court
Earth City, MO 63045
NCPDP ID: 2635564

NOTE: If you’re having trouble finding Foundation Care pharmacy, be sure you are searching “Retail Pharmacy” in the state of Missouri. For more assistance, chat with us here or call DermiraConnect.

icon of number 2
Bookmark Foundation Care as a favorite in your e-prescribing system for future use
Step 3 Icon
Please ensure all patient information is included to avoid prescription delays

You will be contacted within 24 hours if a prior authorization or other clarification is needed

Understand your patient’s QBREXZA journey

  • Following a new prescription, Foundation Care contacts your patient to welcome him or her to therapy. FoundationCare will be calling from a 314 area code. Please ensure that your patient answers this call to help the stay on track with QBREXZA.
  • Once coverage is verified, Foundation Care works with your patient to coordinate delivery
  • Foundation Care sends prescription status updates as needed and contacts you if a patient cannot be reached
  • Ongoing patient support includes refill reminders and links to patient education

For additional resources and program information, visit www.FoundCare.com or call Foundation Care at (877) 291-1122, Monday-Friday, 8 am-6 pm CST.


QBREXZA is an anticholinergic indicated for topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older.


Contraindications: QBREXZA is contraindicated in patients with medical conditions that can be exacerbated by the anticholinergic effect of QBREXZA (e.g., glaucoma, paralytic ileus, unstable cardiovascular status in acute hemorrhage, severe ulcerative colitis, toxic megacolon complicating ulcerative colitis, myasthenia gravis, Sjogren’s syndrome).


Worsening of Urinary Retention: QBREXZA should be used with caution in patients with a history or presence of documented urinary retention. Prescribers and patients should be alert for signs and symptoms of urinary retention (e.g., difficulty passing urine, distended bladder), especially in patients with prostatic hypertrophy or bladder-neck obstruction. Instruct patients to discontinue use immediately and consult a physician should any of these signs or symptoms develop. Patients with a history of urinary retention were not included in the clinical studies.

Control of Body Temperature: In the presence of high ambient temperature, heat illness (hyperpyrexia and heat stroke due to decreased sweating) can occur with the use of anticholinergic drugs such as QBREXZA. Advise patients using QBREXZA to watch for generalized lack of sweating when in hot or very warm environmental temperatures and to avoid use if not sweating under these conditions.

Operating Machinery or an Automobile: Transient blurred vision may occur with use of QBREXZA. If blurred vision occurs, the patient should discontinue use until symptoms resolve. Patients should be warned not to engage in activities that require clear vision such as operating a motor vehicle or other machinery, or performing hazardous work until the symptoms have resolved.


The most common adverse reactions seen in ≥2% of subjects treated with QBREXZA were dry mouth (24.2%), mydriasis (6.8%), oropharyngeal pain (5.7%), headache (5.0%), urinary hesitation (3.5%), vision blurred (3.5%), nasal dryness (2.6%), dry throat (2.6%), dry eye (2.4%), dry skin (2.2%) and constipation (2.0%). Local skin reactions, including erythema (17.0%), burning/stinging (14.1%) and pruritus (8.1%) were also common.


Anticholinergics: Coadministration of QBREXZA with anticholinergic medications may result in additive interaction leading to an increase in anticholinergic adverse effects. Avoid coadministration of QBREXZA with other anticholinergic-containing drugs.


Instruct patients to use one cloth to apply QBREXZA to both axillae by wiping the cloth across one underarm, ONE TIME. Using the same cloth, apply the medication to the other underarm, ONE TIME. Inform patients that QBREXZA can cause temporary dilation of the pupils and blurred vision if it comes in contact with the eyes.

Instruct patients to wash their hands with soap and water immediately after discarding the used cloth.


Pregnancy: There are no available data on QBREXZA use in pregnant women to inform a drug-associated risk for adverse developmental outcomes.

Lactation: There are no data on the presence of glycopyrrolate or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for QBREXZA and any potential adverse effects on the breastfed infant from QBREXZA or from the underlying maternal condition.

Renal Impairment: The elimination of glycopyrronium is severely impaired in patients with renal failure.

Please see Full Prescribing Information.